Screener
Kura Oncology KURA EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Kura Oncology in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: Kura Oncology’s 10-Q, filed August 12, 2026. Open the filing →
- Filed
- Aug 12, 2026, 4:15 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-346884
FAQ
- What is Kura Oncology's EPS (diluted)?
- Kura Oncology (KURA) reported EPS (diluted) of -$0.77 in Q2 2026.
- How has Kura Oncology's EPS (diluted) changed year-over-year?
- Kura Oncology's EPS (diluted) decreased by 2.7% year-over-year, from -$0.75 to -$0.77.
- What is the long-term trend for Kura Oncology's EPS (diluted)?
- Over 4 years (2021 to 2025), Kura Oncology's EPS (diluted) has grown at a 12.7% compound annual growth rate (CAGR), from -$1.97 to -$3.18.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about Kura Oncology's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude